Vivozon Pharmaceutical Co., Ltd.

A082800

KR7082800004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
2,945 ^KRW	+4.06%		+3.33%	-1.83%

2023	Tranche Update on Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 19, 2023.	CI
2023	Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 19, 2023, has closed with 5,000,000 shares.	CI

Vivozon Healthcare, Inc.(KOSDAQ:A082800) dropped from S&P Global BMI Index

August 26, 2022 at 05:00 am

Latest news about Vivozon Pharmaceutical Co., Ltd.

Tranche Update on Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 19, 2023.	21/09/23	CI
Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 19, 2023, has closed with 5,000,000 shares.	19/09/23	CI
Vivozon Pharmaceutical Co., Ltd. announces an Equity Buyback for 5,000,000 shares.	19/09/23	CI
Vivozon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	18/09/23	CI
Vivozon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 2.000000072 billion in funding	27/02/23	CI
Vivozon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 2.000000072 billion in funding	08/01/23	CI
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 6 billion in funding	19/12/22	CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 6 billion in funding	10/11/22	CI
Vivozon Healthcare, Inc.(KOSDAQ:A082800) dropped from S&P Global BMI Index	26/08/22	CI
Vivozon Healthcare, Inc. announced that it has received KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors	04/04/22	CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors	24/03/22	CI
Vivozon Healthcare, Inc. announced that it has received KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.	16/12/21	CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.	09/05/21	CI
Osung Advanced Materials Co., Ltd. cancelled the acquisition of Rumi Technology & Loan CO.,LTD. from Lumimicro Co., Ltd for KRW 33.7 billion.	16/01/21	CI
December Fund 3, Nikkei Fund 3 and Pureun Fund 1 cancelled the acquisition of 23.85% stake in Lumimicro Co., Ltd from Osung Advanced Materials Co., Ltd. and S-MAC CO., Ltd..	17/11/20	CI
Vivozon Healthcare, Inc. announced that it has received KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.	04/11/20	CI
Lumimicro Co., Ltd completed the acquisition of 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop, Industrial Bank of Korea and others.	29/09/20	CI
Lumimicro Co., Ltd agreed to acquire 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop, Industrial Bank of Korea and others for KRW 60.9 billion.	22/09/20	CI
Vivozon Healthcare, Inc.(KOSDAQ:A082800) added to S&P Global BMI Index	21/09/20	CI
Vivozon Inc. announced that it has received KRW 49.9999865 billion in funding from Vivozon Healthcare, Inc.	30/06/20	CI
Vivozon Inc. announced that it expects to receive KRW 49.9999865 billion in funding from Lumimicro Co., Ltd	15/06/20	CI
S-MAC CO., Ltd. completed the acquisition of additional 8.22% stake in Kumho HT, Inc. from Lumimicro Co., Ltd.	11/06/20	CI
Lumimicro Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.	05/05/20	CI
Lumimicro Co., Ltd announced that it has received KRW 20 billion in funding	30/01/20	CI

Chart Vivozon Pharmaceutical Co., Ltd.

Duration

Period

More charts

Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VIVOZON PHARMACEUTICAL CO., LTD.	-1.83%	97.8M
ELI LILLY AND COMPANY	+38.51%	728B
NOVO NORDISK A/S	+33.05%	603B
JOHNSON & JOHNSON	-6.23%	360B
MERCK & CO., INC.	+18.78%	332B
ABBVIE INC.	+1.35%	279B
ASTRAZENECA PLC	+16.00%	244B
NOVARTIS AG	+8.09%	207B
ROCHE HOLDING AG	-5.77%	205B
AMGEN INC.	+6.19%	164B